Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Capital Expenditures: 2019-2024

Historic Capital Expenditures for Apellis Pharmaceuticals (APLS) over the last 6 years, with Dec 2024 value amounting to $403,000.

  • Apellis Pharmaceuticals' Capital Expenditures was N/A to $148,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $225,000, marking a year-over-year change of. This contributed to the annual value of $403,000 for FY2024, which is 47.87% down from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Capital Expenditures of $403,000 as of FY2024, which was down 47.87% from $773,000 recorded in FY2023.
  • Apellis Pharmaceuticals' Capital Expenditures' 5-year high stood at $5.4 million during FY2020, with a 5-year trough of $403,000 in FY2024.
  • Its 3-year average for Capital Expenditures is $900,000, with a median of $773,000 in 2023.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Capital Expenditures surged by 220.26% in 2020 and then slumped by 79.66% in 2021.
  • Apellis Pharmaceuticals' Capital Expenditures (Yearly) stood at $5.4 million in 2020, then tumbled by 79.66% to $1.1 million in 2021, then surged by 38.17% to $1.5 million in 2022, then slumped by 49.28% to $773,000 in 2023, then crashed by 47.87% to $403,000 in 2024.